Olezarsen (Tryngolza) for Severe Hypertriglyceridemia

“As a physician, I have seen firsthand how challenging it can be for patients with sHTG to lower their triglycerides below 500 mg/dL, despite background lipid-lowering therapies and lifestyle changes, which leaves them at risk of a devastating and potentially life-threatening acute pancreatitis attack. TRYNGOLZA is a transformational new therapy that showed unprecedented, clinically meaningful outcomes for sHTG, with the potential to redefine the treatment paradigm.”

“Acute pancreatitis is a painful and potentially life-threatening condition that often requires urgent hospitalisation. People with triglyceride levels above 10 mmol/L have a four times greater risk of acute pancreatitis compared to those with ideal low levels, and this risk increases progressively as triglyceride levels rise. According to EAS/ESC guidelines, triglyceride levels above 10 mmol/L warrant urgent intervention to prevent acute pancreatitis.”

“These results add to the collective body of evidence for olezarsen, showing the reduction of acute pancreatitis risk in severe hypertriglyceridemia. As rates of acute pancreatitis continue to increase, olezarsen has the potential to be an important part of a preventative approach to disease management in at-risk patients.”